Tourmaline Bio, Inc. Expected to Post Q2 2024 Earnings of ($0.57) Per Share (NASDAQ:TRML)

Tourmaline Bio, Inc. (NASDAQ:TRMLFree Report) – Research analysts at Leerink Partnrs reduced their Q2 2024 EPS estimates for Tourmaline Bio in a report issued on Monday, May 13th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($0.57) per share for the quarter, down from their prior estimate of ($0.50). The consensus estimate for Tourmaline Bio’s current full-year earnings is ($2.90) per share. Leerink Partnrs also issued estimates for Tourmaline Bio’s Q3 2024 earnings at ($0.62) EPS, Q4 2024 earnings at ($0.66) EPS, FY2024 earnings at ($2.41) EPS, FY2025 earnings at ($3.30) EPS, FY2026 earnings at ($4.25) EPS, FY2027 earnings at ($5.51) EPS and FY2028 earnings at ($3.47) EPS.

Tourmaline Bio (NASDAQ:TRMLGet Free Report) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.55) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.13.

A number of other research analysts also recently issued reports on TRML. Truist Financial reissued a “buy” rating and issued a $74.00 price objective on shares of Tourmaline Bio in a research note on Monday, March 25th. Jefferies Financial Group boosted their price target on Tourmaline Bio from $41.00 to $72.00 and gave the company a “buy” rating in a research note on Wednesday, March 20th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $48.00 price objective on shares of Tourmaline Bio in a research report on Tuesday. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Tourmaline Bio presently has a consensus rating of “Buy” and a consensus price target of $61.80.

View Our Latest Stock Analysis on Tourmaline Bio

Tourmaline Bio Stock Up 5.8 %

Shares of NASDAQ TRML opened at $15.25 on Thursday. The company has a market capitalization of $391.16 million, a PE ratio of -2.35 and a beta of 2.42. Tourmaline Bio has a twelve month low of $9.18 and a twelve month high of $48.31. The firm has a fifty day simple moving average of $23.51 and a 200 day simple moving average of $25.90.

Institutional Investors Weigh In On Tourmaline Bio

Hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets bought a new stake in Tourmaline Bio during the 1st quarter valued at $31,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Tourmaline Bio by 109.5% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 4,939 shares of the company’s stock worth $113,000 after acquiring an additional 2,582 shares during the last quarter. Denali Advisors LLC acquired a new stake in shares of Tourmaline Bio in the 1st quarter worth about $128,000. Jump Financial LLC bought a new position in Tourmaline Bio in the 4th quarter valued at about $380,000. Finally, Nan Fung Group Holdings Ltd acquired a new position in Tourmaline Bio during the 1st quarter valued at about $481,000. Institutional investors own 91.89% of the company’s stock.

About Tourmaline Bio

(Get Free Report)

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.

See Also

Earnings History and Estimates for Tourmaline Bio (NASDAQ:TRML)

Receive News & Ratings for Tourmaline Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tourmaline Bio and related companies with MarketBeat.com's FREE daily email newsletter.